News and Announcements
Emerging Markets Solar Fund
- Published November 15, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The Invictus Emerging Markets Solar Fund offers investment in a portfolio of Solar Energy Infrastructure Assets in Emerging Markets. The EMS fund aims to earn stable, consistent and healthy returns while contributing to global clean energy production.
The fund’s strategy will be to invest in a diversified portfolio of solar energy infrastructure projects, which are insured and repaid through a fixed-term lease. The fund will deploy funding across multiple projects with different geographical, commercial and return profiles to provide a degree of downside risk protection.
The fund aims to utilize 95% of fund assets to invest in solar infrastructure projects in emerging markets via the Sun Exchange. All returns earned on infrastructure financing are reinvested in the fund. Assets not deployed into solar projects will be invested in the Invictus Margin Lending fund or serve as a liquidity pool for investors looking to redeem their tokens. The EMS fund is an open ended fund with no lock-up; investors have access to next day redemptions. The fund issues blockchain tokens; all fund transactions can be verified on the blockchain.
Find out more here
About CRYPTO10
CRYPTO10 Hedged (C10) is a Smart Index Fund of the top 10 cryptocurrencies. The C10 fund is rebalanced weekly. Asset allocation is capped at 15%. Fund investors have immediate ability to redeem investments 24/7 (i.e. no lock-up). Crypto10 Hedged is an open fund with a dynamic cash hedge that allocates a portion of funds to cash in a declining market to reduce drawdown. Extensively backtested, fund rules are scientifically optimised for market beating returns; outperforming the often volatile large cap cryptocurrencies.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
